1 April 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 871,411 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.

Share Options were granted as follows:

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, including any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 31 March 2021. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 3,191,161, representing approximately 3.80% of its current issued share capital of 84,063,923.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.